GHRP-2

Growth Hormone Releasing Peptide-2

GHRP-2 (Growth Hormone Releasing Peptide-2), also known as pralmorelin, is a synthetic hexapeptide that acts as a potent agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R). It triggers pulsatile growth hormone release from the pituitary gland, mimicking the body's natural GH secretion patterns. GHRP-2 was developed as a diagnostic agent and is clinically approved in Japan for assessing growth hormone deficiency. Unlike direct GH administration, GHRP-2 works through the body's natural pathways, making it a preferred option for those seeking to enhance their natural growth hormone production safely and effectively.

Clinical Safety Profile

Reported Side Effects

Increased appetite

Water retention

Tingling sensations

Facial flushing

Joint stiffness (mild)

Side Effect Management (Clinical Trial Data)

Side Effect Management Strategies

Nausea: Take with food, smaller meals, ginger supplements

Vomiting: Slower dose escalation, anti-emetics if severe

Diarrhea: Adequate hydration, probiotics, bland diet

Constipation: Increase fiber intake, adequate fluids, light exercise

Clinical Safety Metrics

Good

Overall Safety Rating

12.4%

Discontinuation Rate

Research

Approved Status

CONTRAINDICATIONS

• Active cancer or history of malignancy

• Diabetic retinopathy

• Pregnancy or breastfeeding

• Severe kidney or liver disease

Medical Disclaimer

Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.

Peptide Database